Search Results for "f"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for f. Results 301 to 310 of 864 total matches.

Radiofrequency Catheter Ablation for Treatment of Cardiac Arrhythmias

   
The Medical Letter on Drugs and Therapeutics • Apr 26, 1996  (Issue 973)
was successful in 19 of 20 patients, and no recurrences were reported during one year of follow-up (F Morady et ...
In recent years, selective destruction of cardiac tissue by radiofrequency energy has become a routine procedure for treatment of some types of cardiac arrhythmias, particularly supraventricular tachycardias (MM Scheinman, Pacing Clin Electrophysiol, 18:1474, 1995).
Med Lett Drugs Ther. 1996 Apr 26;38(973):40-2 |  Show IntroductionHide Introduction

Terbinafine for Onychomycosis

   
The Medical Letter on Drugs and Therapeutics • Aug 16, 1996  (Issue 981)
and persists in the nails for up to 36 weeks after it is stopped (F Schatz et al, Clin Exp Dermatol, 20:377 ...
Terbinafine (Lamisil - Sandoz), an allylamine synthetic antifungal, previously available in the USA in a topical formulation (Medical Letter, 35:76, 1993) has now been marketed for oral use in the treatment of fungal nail infections caused by dermatophytes. Oral terbinafine has been available in Europe since 1992.
Med Lett Drugs Ther. 1996 Aug 16;38(981):72-4 |  Show IntroductionHide Introduction

Esomeprazole (Nexium)

   
The Medical Letter on Drugs and Therapeutics • Apr 30, 2001  (Issue 1103)
., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS ...
Esomeprazole magnesium (Nexium - AstraZeneca), the S-isomer of omeprazole (Prilosec), is the fifth benzimidazole proton pump inhibitor to become available in the United States. Omeprazole, which was the first, is going off patent this year.
Med Lett Drugs Ther. 2001 Apr 30;43(1103):36-7 |  Show IntroductionHide Introduction

Gleevec (STI-571) For Chronic Myeloid Leukemia

   
The Medical Letter on Drugs and Therapeutics • Jun 11, 2001  (Issue 1106)
, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University ...
Imatinib mesylate (STI-571; Gleevec - Novartis), an oral tyrosine kinase inhibitor, has received accelerated approval from the FDA for treatment of all phases of chronic myeloid leukemia (CML) after interferon has failed.
Med Lett Drugs Ther. 2001 Jun 11;43(1106):49-50 |  Show IntroductionHide Introduction

Ertapenem (Invanz) - A New Parenteral Carbapenem

   
The Medical Letter on Drugs and Therapeutics • Mar 18, 2002  (Issue 1126)
., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS ...
Ertapenem (er ta pen' em; Invanz - Merck), a carbapenem antibacterial with a narrower spectrum of activity than imipenem (Primaxin) or meropenem (Merrem), has been approved by the FDA for once-daily IV treatment of complicated intra-abdominal, urinary tract and skin and skin structure infections, acute pelvic infections, and community-acquired pneumonia.
Med Lett Drugs Ther. 2002 Mar 18;44(1126):25-6 |  Show IntroductionHide Introduction

Bosentan (Tracleer) for Pulmonary Arterial Hypertension

   
The Medical Letter on Drugs and Therapeutics • Apr 01, 2002  (Issue 1127)
Meinertz, M.D., University Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F ...
Bosentan (Tracleer - Actelion), a non-peptide endothelin receptor antagonist, has been approved by the FDA for oral treatment of patients who have pulmonary arterial hypertension (PAH) with symptoms of dyspnea at rest or with minimal exertion.
Med Lett Drugs Ther. 2002 Apr 1;44(1127):30-2 |  Show IntroductionHide Introduction

New Treatments for Actinic Keratoses

   
The Medical Letter on Drugs and Therapeutics • Jun 24, 2002  (Issue 1133)
., University Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D ...
Several new treatments are now available for actinic keratoses (AKs), scaly pink papules commonly found on sun-exposed areas of the face, scalp, forearms and dorsal surface of the hands, particularly in the elderly. Some AKs regress spontaneously, but a few may progress to squamous cell carcinoma; the risk of progression has been estimated to be about 0.25% to 1% per year (EWB Jeffes III and EH Tang, Am J Clin Dermatol 2000; 1:167).
Med Lett Drugs Ther. 2002 Jun 24;44(1133):57-8 |  Show IntroductionHide Introduction

Olmesartan (Benicar) for hypertension

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2002  (Issue 1136)
Meinertz, M.D., University Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F ...
Olmesartan medoxomil (Benicar - Sankyo), a substituted imidazole, is the seventh oral angiotensin II receptor blocker (ARB) approved by the FDA for treatment of hypertension.
Med Lett Drugs Ther. 2002 Aug 5;44(1136):69-70 |  Show IntroductionHide Introduction

Tests for Drugs of Abuse

   
The Medical Letter on Drugs and Therapeutics • Aug 19, 2002  (Issue 1137)
., University Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D ...
Testing for drug use has become increasingly common, not only in health care, but also in drug rehabilitation, in the military, at the workplace, after accidents and in the criminal justice system. Performance-enhancing drugs such as anabolic steroids, growth hormone (Genotropin, and others) and erythropoietin (Procrit, Epogen) are not discussed here.
Med Lett Drugs Ther. 2002 Aug 19;44(1137):71-3 |  Show IntroductionHide Introduction

Treprostinil (Remodulin) for Pulmonary Arterial Hypertension

   
The Medical Letter on Drugs and Therapeutics • Sep 16, 2002  (Issue 1139)
, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University ...
Treprostinil sodium (tre prost' in il; Remodulin - United Therapeutics), a prostacyclin analogue, has been approved by the FDA for continuous subcutaneous (SC) treatment of patients with pulmonary arterial hypertension who have dyspnea on more than minimal exertion (NYHA Class II-IV).
Med Lett Drugs Ther. 2002 Sep 16;44(1139):80-2 |  Show IntroductionHide Introduction